Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of 3,4-methylenedioxymethamphetamine (MDMA) on Startle Response

NCT03181763 is registered in ClinicalTrials.gov with Resilient Pharmaceuticals as lead sponsor.

NCT NCT03181763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of 3,4-methylenedioxymethamphetamine (MDMA) on Startle Response
Lead sponsor
Resilient Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
March 14, 2017
Completion date
August 1, 2020
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

startle response